【摘要】：目的:將《排便習慣改變脾氣虛證癥狀分級量化表》用作參照,對益氣升降湯方治療大腸癌術后患者化療期間出現(xiàn)排便習慣改變的效應作出評價,同時觀察、監(jiān)測并記錄患者治療的細胞免疫功能、KPS評分、腫瘤標記物水平、腫瘤復發(fā)轉移情況及化療時發(fā)生的毒副反應,并進行前后對比和分析,由此為益氣升降湯治療大腸癌術后排便異常在臨床上推行及廣泛應用,為研發(fā)新的抗癌中藥制劑提供理論依據(jù)與新的契機。方法:針對收集的已確診大腸癌術后患者(60例)展開隨機對照臨床試驗研究,按亂數(shù)表法將其分為治療組和對照組(各30例)。其中接受益氣升降湯方聯(lián)合FOLFOX4方案化療者為治療組,單純接受FOLFOX4方案化療者為對照組,14天為1周期,連續(xù)觀察4周期。把《排便習慣改變脾氣虛證癥狀分級量化表》作為益氣升降湯所產(chǎn)生治療效應的主要評定標準,并觀察比較常用的療效性及安全性檢測指標在治療前后的變化。結果:使用益氣升降湯中藥聯(lián)合FOLFOX方案化療的患者在大便次數(shù)、頻繁便意感/肛門下墜/不盡/脹感方面的前后評分差異有高度統(tǒng)計學意義(P0.01),在糞便性狀,排便時間、排便困難/過度用力排便、腸鳴亢進的方面的前后評分差異有統(tǒng)計學意義(P0.05);該組經(jīng)治療后在糞便性狀、排便困難/過度用力排便、頻繁便意感/肛門下墜/不盡/脹感、體倦乏力、惡心嘔吐方面與單用FOLFOX方案化療的評分差異有統(tǒng)計學意義(P0.05);此外結果提示,經(jīng)秩和檢驗,該組治療方法對增加患者細胞免疫功能及體力狀況,降低腫瘤指標及化療毒副作用發(fā)生率方面的優(yōu)勢強于對照組,差異有統(tǒng)計學意義(P0.05)。結論:益氣升降湯方在化療期間治療大腸癌術后患者的排便習慣改變,能夠減輕臨床癥狀,調(diào)節(jié)細胞免疫功能,改善體力狀況,在一定程度上能夠降低腫瘤標記物值,同時化療毒副作用輕,值得臨床運用。
[Abstract]:Objective:To evaluate the effect of Yiqi Shengjiang Decoction on the change of defecation habits in patients with colorectal cancer after chemotherapy, and to monitor and record the cellular immune function, KPS score, tumor marker level, tumor recurrence and metastasis. The toxicity and side effects of chemotherapy were compared and analyzed before and after treatment, which provided a theoretical basis and a new opportunity for the clinical application of Yiqi Shengjiang Decoction in the treatment of abnormal bowel movements after colorectal cancer surgery, and for the development of New Anticancer Traditional Chinese medicine preparations. The treatment group was treated with Yiqi Shengjiang Decoction combined with FOLFOX4 regimen chemotherapy, and the control group was treated with FOLFOX4 regimen chemotherapy alone. The patients received FOLFOX4 regimen chemotherapy for a period of 14 days for four consecutive cycles of observation. In order to evaluate the therapeutic effect of Yiqi Shengjiang Decoction and observe the changes of the commonly used efficacy and safety indexes before and after treatment.Results:There were significant differences in the scores of fecal frequency, frequent fecal feeling/anal falling/unexhausted/distension between the patients treated with Yiqi Shengjiang Decoction and FOLFOX regimen chemotherapy. Highly statistically significant (P 0.01), there were significant differences in stool traits, defecation time, dyspepsia / overexertion defecation, hypersonic bowel sounds (P 0.05); the group after treatment in the stool traits, dyspepsia / overexertion defecation, frequent fecal sense / anal drop / endless / distension, fatigue, nausea and vomiting There was significant difference between FOLFOX regimen and FOLFOX regimen alone (P 0.05). In addition, the results showed that the treatment group had more advantages than the control group in increasing cellular immune function and physical status, reducing tumor indicators and the incidence of side effects of chemotherapy, and the difference was statistically significant (P 0.05). Jiangtang Decoction can alleviate clinical symptoms, regulate cellular immune function, improve physical condition, to a certain extent, reduce the value of tumor markers, while the side effects of chemotherapy are mild, which is worthy of clinical application.
【學位授予單位】：南京中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R735.34

【參考文獻】

相關期刊論文 前10條

1 徐敬宣;錢曉萍;林黎;薛姣;胡靜;楊陽;胡文靜;劉寶瑞;;石見穿活性部位的體外抗腫瘤作用研究[J];現(xiàn)代腫瘤醫(yī)學;2015年12期

2 李枋霏;何莉莎;賈程輝;李杰;;基于氣機升降理論治療腸癌術后腸道功能紊亂[J];中醫(yī)雜志;2014年16期

3 梁啟超;劉爽;李榮輝;才玉婷;吳宜艷;;石見穿多糖的提取及抗腫瘤活性[J];光譜實驗室;2013年03期

4 錢曉萍;徐敬宣;林黎;薛姣;胡靜;楊陽;胡文靜;劉寶瑞;;中藥石見穿提取物熊果酸體外抑制腫瘤細胞增殖的實驗研究[J];現(xiàn)代腫瘤醫(yī)學;2012年11期

5 任金冬;任峰;周�？�;宋明旭;;聯(lián)合檢測血清腫瘤標志物在大腸癌診斷中的價值[J];中外醫(yī)學研究;2012年31期

6 張善蘭;錢曉萍;劉寶瑞;胡靜;萬莉;李茹恬;禹立霞;;石見穿醇提取物對血管內(nèi)皮細胞生物學行為的影響[J];江蘇醫(yī)藥;2012年11期

7 柳芳;劉建勛;任鈞國;李軍梅;李鴻海;;石見穿提取物通過阻斷血管生成抑制腫瘤生長的研究[J];中國中藥雜志;2012年09期

8 李猛;;中醫(yī)藥治療晚期大腸癌的近期療效觀察[J];河北中醫(yī)藥學報;2011年02期

9 趙仁;李衛(wèi)強;楊治花;朱西杰;;益氣養(yǎng)陰基本方對直腸癌放療后氣陰兩虛證患者的療效及其免疫功能的影響[J];時珍國醫(yī)國藥;2011年03期

10 丁紀元;王雍;李俊;;枳術黃芪湯加減治療腫瘤化療后便秘50例[J];江西中醫(yī)藥;2010年09期

，

本文編號：2243517